Brokerages predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report earnings of ($0.33) per share for the current quarter, Zacks reports. Two analysts have made estimates for Inovio Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.32). Inovio Pharmaceuticals reported earnings per share of ($0.40) during the same quarter last year, which suggests a positive year over year growth rate of 17.5%. The company is expected to issue its next earnings report on Wednesday, November 14th.
On average, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.07) per share for the current financial year, with EPS estimates ranging from ($1.09) to ($1.05). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.25) to ($1.07). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.22). The business had revenue of $1.53 million during the quarter, compared to the consensus estimate of $7.50 million. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. During the same quarter in the prior year, the company earned ($0.31) earnings per share.
A number of equities analysts have weighed in on the company. Maxim Group set a $8.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 10th. BidaskClub upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 18th. ValuEngine upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 18th. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 16th. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $11.25.
In other news, CFO Peter Kies sold 35,000 shares of the stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total transaction of $155,400.00. Following the transaction, the chief financial officer now directly owns 97,088 shares in the company, valued at approximately $431,070.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.40% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in INO. Levin Capital Strategies L.P. grew its position in Inovio Pharmaceuticals by 80.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 16,500 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $150,000. Emerald Advisers Inc. PA bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $228,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Inovio Pharmaceuticals by 50.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 33,825 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Inovio Pharmaceuticals by 11.2% during the 4th quarter. Teachers Advisors LLC now owns 159,972 shares of the biopharmaceutical company’s stock worth $661,000 after acquiring an additional 16,104 shares during the last quarter. Hedge funds and other institutional investors own 32.56% of the company’s stock.
NASDAQ INO traded up $0.10 during trading on Friday, reaching $4.46. The company’s stock had a trading volume of 416,780 shares, compared to its average volume of 682,208. The firm has a market capitalization of $398.93 million, a P/E ratio of -4.09 and a beta of 1.67. Inovio Pharmaceuticals has a one year low of $3.64 and a one year high of $7.00.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.